Michael McAuliff

Drugmakers’ Spending on Stock, Dividends and Executive Pay Exceeds Research, Democrats Say

KHN Original

The pharmaceutical industry argues that large profits are needed to fund extensive research and innovation. But Democrats on the House Oversight and Reform Committee, seeking to bolster their effort to let Medicare negotiate drug prices, say major drug companies plow more of their billions in earnings back into propping up their stock and enriching executives and shareholders.